Loading…

Portal-Mesenteric Vein Resection in Borderline Pancreatic Cancer; 33 Month-Survival in Patients with Good Performance Status

Background: Patients with pancreatic cancer (PC), which is not upfront resectable, but borderline, involving major peripancreatic vessels, have not been generally considered for surgery, considering that resection in such a setting may be futile. Materials and Methods: Retrospective analysis of pros...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pancreatic cancer 2019-09, Vol.5 (1), p.43-50
Main Authors: Tsiotos, Gregory G., Ballian, Nikiforos, Michelakos, Theodoros, Milas, Fotios, Ziogou, Panoraia, Papaioannou, Dimitrios, Salla, Charitini, Athanasiadis, Ilias, Razis, Evangelia, Stavridi, Flora, Psomas, Maria
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Patients with pancreatic cancer (PC), which is not upfront resectable, but borderline, involving major peripancreatic vessels, have not been generally considered for surgery, considering that resection in such a setting may be futile. Materials and Methods: Retrospective analysis of prospectively collected data on patients with borderline pancreatic adenocarcinoma undergoing pancreatectomy en-block with portal and/or superior mesenteric vein resection in a tertiary referral center in Greece between January 2012 and February 2017. Follow-up was complete up to January 2018. Results: Twenty-four patients were included. Neoadjuvant therapy (NAT) was administered to only 38%, but more commonly in the second half of the group (58% vs. 17%, p = 0.035). It was associated with smaller tumor size (median: 2.5 vs. 4.2 cm, p 
ISSN:2475-3246
2475-3246
DOI:10.1089/pancan.2019.0013